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Abstract

Go to:

Development of higher rates of nondiabetic glomerulosclerosis (GS) in African Americans has been
attributed to two coding sequence variants (G1 and G2) in the APOL1 gene. To date, the cellular function
and the role of APOL1 variants (Vs) in GS are still unknown. In this study, we examined the effects of
overexpressing wild-type (G0) and kidney disease risk variants (G1 and G2) of APOL1 in human
podocytes using a lentivirus expression system. Interestingly, G0 inflicted podocyte injury only at a higher
concentration; however, G1 and G2 promoted moderate podocyte injury at lower and higher
concentrations. APOL1Vs expressing podocytes displayed diffuse distribution of both Lucifer yellow dye
and cathepsin L as manifestations of enhanced lysosomal membrane permeability (LMP). Chloroquine
attenuated the APOL1Vs-induced increase in podocyte injury, consistent with targeting lysosomes. The
chloride channel blocker DIDS prevented APOL1Vs- induced injury, indicating a role for chloride influx
in osmotic swelling of lysosomes. Direct exposure of noninfected podocytes with conditioned media from
G1- and G2-expressing podocytes also induced injury, suggesting a contributory role of the secreted
component of G1 and G2 as well. Adverse host factors (AHFs) such as hydrogen peroxide, hypoxia, TNFα, and puromycin aminonucleoside augmented APOL1- and APOL1Vs-induced podocyte injury, while the
effect of human immunodeficiency virus (HIV) on podocyte injury was overwhelming under conditions of
APOLVs expression. We conclude that G0 and G1 and G2 APOL1 variants have the potential to induce
podocyte injury in a manner which is further augmented by AHFs, with HIV infection being especially
prominent.
Keywords: APOL1 risk variants, kidney disease, podocyte, necrosis, lysosomal membrane permeability
AFRICAN AMERICANS (AAS) DEVELOP

higher rates of progressive nephropathy, including focal segmental
glomerulosclerosis (FSGS), human immunodeficiency virus (HIV)-associated nephropathy (HIVAN), and
hypertension-associated end-stage kidney disease (ESKD) compared with European Americans (EAs) (25,
37, 43). This disparity is the most pronounced in the case of HIVAN, reaching a disparity which is >10fold (25). This overwhelming population disparity between AAs and EAs and, greater familial clustering
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable

1/23

5/15/2018

APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability

among AAs, point to a prominent contribution of underlying genetic factor(s) (14). Recently, increasing
evidence has shown that this major health disparity is strongly associated with two coding sequence
variants (G1 and G2) in APOL1 (12, 15, 19, 42).
APOL1 is located at chromosome 22q13.1, and it encodes the minor apolipoprotein L1 component of
HDL. This apolipoprotein is expressed in the liver, pancreas, kidney, and brain and in macrophages,
endothelial, and several other cell types (9, 10). The G1 variant (rs73885319) is a compound missense
mutation (S342G:I384M) encoding two nonsynonymous amino acids. The G2 variant is a 6-bp in-frame
deletion which has resulted in the loss of two amino acids (N388 and Y389) at the C-terminal helix of
APOL1 (18, 48). These two allelic variants arose on separate human phylogenetic lineages, and they have
never been observed together on the same parental chromosome. Approximately 34% of AAs possess one
of the two risk variants (APOL1Vs), and ∼13% have both coding variants (18, 25, 48). In the United
States, ∼3 million AAs carry both risk alleles. In contrast, APOL1Vs occur infrequently in EAs, ∼0.3%
carry G1 and 0.1% G2 alleles. These studies are consistent with African admixture (18, 25, 48). Wild-type
(WT) APOL1 circulates in plasma and has the ability to kill the trypanosome (Trypanosome brucei)
responsible for causing sleeping sickness in cattle.
The Trypanosoma brucei rhodesiense (Tbr) subspecies is resistant to the trypanolytic effect of APOL1.
This is due to the presence of a serum resistance-associated (SRA) factor. SRA allows for Tbr to induce
human sleeping sickness (25, 44). The G1 and G2 coding variants confer resistance, in humans, to Tbr.
The presence of even a single variant has been shown to confer resistance. Thus these variants have gained
prominence in parts of the world with significant rates of sleeping sickness. The risk allele state is now
highly associated with increased risk for major forms of nondiabetic kidney disease in descendants,
including AAs (18, 19, 25, 42, 48). Recent clinical studies have also implicated the coding variants with
renal allograft failure (24, 38). In these studies, kidneys donated from deceased donors with APOL1Vs
lasted for shorter periods, independently of recipient ancestry.
Although clinical studies have clearly shown a strong association of APOL1Vs with progressive
nondiabetic kidney disease, the cellular function and the role of APOL1Vs in the pathogenesis of kidney
injury are still unknown. Localization studies have implicated the podocyte as a target (31). Most
proteinuric diseases including glomerular sclerosis and HIVAN are associated with podocytopathy (altered
podocyte phenotype, reduction in number, and effacement of foot processes) and tubulopathy (32, 33).
In the present study, we examined the effect of APOL1WT (G0) and APOL1Vs (G1 and G2) on human
podocytes. Additionally, we have studied the mechanism involving APOL1Vs-induced podocyte injury.

MATERIALS AND METHODS

Go to:

Culture of human podocytes. Human podocytes were cultured as previously reported (27, 40). Briefly,

immortalized human podocytes proliferated in the growth medium containing RPMI 1640 supplemented
with 10% fetal bovine serum, 1× penicillin-streptomycin, 1 mM L-glutamine, and 1× insulin, transferrin,
and selenium (ITS; Invitrogen, Grand Island, NY) at permissive temperature (33°C). When the cells
attained ∼80% confluence, they were transferred at 37°C for differentiation in a medium without ITS for
5–7 days.
Production of pseudotyped retroviral supernatant and transduction of podocytes. Replication-

defective viral supernatants were prepared as published previously (21). Briefly, a green fluorescent
protein (GFP) reporter gene (from pEGFP-C1; Clontech, Palo Alto, CA) was substituted in place of
gag/pol genes in HIV-1 proviral construct pNL4–3. This parental construct (pNL4–3: ΔG/P-GFP) was
used to produce VSV.G pseudotyped viruses to provide pleiotropism and high-titer virus stocks. Infectious
viral supernatants were produced by transient transfection of 293T cells using Effectene (Qiagen). The
HIV-1 gag/pol and VSV.G envelope genes were provided in trans using pCMV R8.91 and pMD2.G
plasmids, respectively (gifts of Dr. Didier Trono, Salk Institute, La Jolla, CA). As a negative control, virus
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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was also produced from pHR-CMV-IRES2-GFP-ΔB, which contained HIV-1 LTRs and a GFP empty
expression vector. The viral stocks were titrated by infecting 293T cells with 10-fold serial dilution. Viral
stocks ranging from 105 to 106 GFP-expressing units (GEU)/ml were obtained. The cells were infected
with MOI of 0.5 GEU for 2 h.
Lentivirus preparation. To amplify the DNA fragments corresponding to the whole APOL1 open reading

frames, a forward primer GGATCCATGGAGGGAGCTGCTTTGCTGAGAG (BamHI cleavage site
underlined) and reverse primer GTCGACTCACAGTTCTTGGTCCGCCTGCAG (SalI cleavage site
underlined) were designed based on the sequences around the initial and stop codons, respectively. The
PCR-amplified products were double-digested with BamHI and SalI and subcloned into a LG12 lentiviral
vector to obtain a transfer plasmid designated LG12-“APOL1” 5. The transcription of targeting genes was
driven by a CMV promoter. psPAX2 was the HIV-derived packaging construct, and the pMD2.G construct
expressed the VSV-G envelope protein. The APOL11 lentivirus was produced by transfection of 293T
cells by using Effectene Transfection Reagent (Qiagen), and the virus titer was determined by using
QuickTiter Lentivirus Titer Kit (Cell Biolabs, San Diego, CA), following the manufacturer's instructions.
Quantitative RT-PCR. Total RNA was isolated from human podocytes using TRIzol reagent (Invitrogen).

Five micrograms of total RNA were reverse transcribed using the first-strand synthesis system
(Invitrogen). Quantitative PCR (qPCR) was carried out in an ABI Prism 7900HT sequence detection
system. The primer sequences were AGGGAGCTGCTTTGCTGAGAGT (APOL1-FW) and
AGTCACCGAGGGGCTTACTTTG (APOL1-RV). GAPDH was used as an internal control, and the
primers were GGGAAGCTCACTGGCATGGCCTTCC (GAPDH-FW) and
CATGTGGGCCATGAGGTCCACCAC (GAPDH-RV).
Lactate dehydrogenase activity detection. After infection with the lentivirus, human podocytes were

cultured in medium containing 1% serum. At 24 h postinfection (hpi), the medium was harvested for
lactate dehydrogenase (LDH) activity detection with a LDH Cytotoxicity Detection Kit (Clontech,
Mountain View, CA) following the manufacturer's instructions.
Trypan blue staining. Differentiated human podocytes were transduced with the lentivirus for 48 h and

then rinsed with PBS to remove the floating cells and cell debris. Cells were detached with Accutase
(Innovative Cell Technologies, San Diego, CA), subsequently labeled with 0.2% trypan blue, and counted
under the light microscope. The unstained cells (white) were considered as live cells, while the blue cells
were dead.
Propidium iodide and Hoechst staining. Proidium iodide (PI) and Hoechst staining was performed as

previously reported (46). Briefly, after appropriate treatment, the culture media was removed from the cells
and fresh media containing Hoechst 33342 (10 μg/ml) was added. Cells were subsequently incubated for
10 min at 37°C. Then, a PI solution was added and the cell dishes were kept on ice for 7 min. Cell images
were taken immediately with a Zeiss microscope (Carl Zeiss MicoImaging, Jena, Germany) equipped with
a digital imaging system.
Assessment of lysosomal structural integrity. Lysosomes were stained with Lucifer yellow (Invitrogen)

and LysoTracker Red (Invitrogen) as described previously (6, 7). Briefly, cells were cultured overnight in
the medium containing 1 mg/ml Lucifer yellow, and then 500 nM LysoTracker was added followed by an
additional 30-min incubation. Then, the medium was removed, and the cells were rinsed three times with
PBS. The cells were then fixed with 4% paraformaldehyde (PFA) for 10 min. The lysosomes were
visualized, and images were captured with a Zeiss microscope. Cathepsin L activity was detected using a
Magic Red Cathepsin L Kit (ImmunoChemistry Technologies, Bloomington, MN) following the
manufacturer's instructions. The F-actin cytoskeleton was visualized using Alexa Fluor 594-conjugated
phalloidin, as previously reported (28).
Western blotting.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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Western blotting was performed as described (26, 27). Briefly, cells were washed with PBS and lysed in
RIPA buffer [1× PBS, pH 7.4, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1.0 mM sodium
orthovanadate, 10 μl of protease inhibitor cocktail (100×, Calbiochem)/1 ml of buffer, and 100 μg/ml
PMSF]. Proteins (20–30 μg) were separated by 12% SDS-PAGE and then transferred to an Immuno-Blot
polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA). After blocking in PBS/Tween
(0.1%) with 5% nonfat milk, the membrane was incubated with primary antibodies overnight at 4°C
followed by horseradish peroxidase-conjugated secondary antibodies (1:3,000, Santa Cruz Biotechnology)
and then developed using Enhanced Chemiluminescent (ECL) solution (Pierce). The primary antibodies
used for immunodetection were goat anti-APOL1 (1:1,000, Santa Cruz Biotechnology) and goat anti-actin
(1:3,000, Santa Cruz Biotechnology). For protein expression quantification, the developed films were
scanned with a CanonScan 9950F scanner, and the acquired images were then analyzed using the public
domain National Institutes of Health image-analysis program
(http://rsb.info.nih.gov.medproxy.hofstra.edu/nih-image/).
Statistical analyses. Data are presented as means ± SD unless otherwise noted. All experiments were

conducted and repeated at least three times with duplicate or triplicate samples in each assay. All data were
evaluated statistically by ANOVA, followed by Newman-Keuls multiple comparison tests using Prism 4.0
(GraphPad Software). In the case of single mean comparison, data were analyzed by Student's t-test. P
values <0.05 were considered as statistically significant.

RESULTS

Go to:

Overexpression of APOL1Vs increases podocyte necrosis. To investigate the role of APOL1Vs in the

induction of podocyte injury, we overexpressed APOL1Vs (G1 and G2) as well as APOL1WT (G0) in
human podocytes employing a GFP-containing lentivirus expression system. Human podocytes were
transduced with the same quantity of lentivirus (titrated as 0.8 pg p24 protein/cell), harboring APOL1WT
or APOL1Vs cDNAs. Transduction efficiency was quantified using GFP expression. It was observed to be
90%. Subsequently, the overexpression of recombinant APOL1 in podocytes was confirmed. For time
course experiments, cell lysates were collected for Western blot assay. Podocytes displayed initial
APOL1WT and Vs expression within 24 h of infection (Fig. 1, A and B), with increasing overexpression
by 48 h (Fig. 1, C and D).
To determine the effect of APOL1WT and Vs on podocyte injury, we overexpressed these variants in
differentiated human podocytes and analyzed podocyte LDH activity. At 24 h, APOL1WT increased
podocyte LDH activity, and podocytes expressing G1/G2 variants exhibited even higher levels of LDH
activity compared with APOL1WT-expressing cells (Fig. 2A).
We then evaluated the effect of APOL1WT (G0) and APOL1Vs (G1 and G2) on podocyte viability using
trypan blue staining. Although both APOL1WT and APOL1Vs displayed an increased number of trypan
blue-positive podocytes compared with noninfected podocytes, nonetheless podocytes expressing either
G1 or G2 constructs displayed a greater number of trypan blue-positive cells compared with G0 (Fig. 2B).
Overexpression of APOL1WT has been reported to induce autophagic cell death in cancer cell lines (47,
49). To determine the type of the cytotoxicity induced by APOL1WT and APOL1Vs, we examined their
effect on podocyte morphology under a phase-contrast microscope. Podocytes transduced with G0 or G1and G2-containing lentiviruses showed a higher percentage of cells expressing a swollen phenotype
compared with the vector alone (Fig. 3, A and B). This swollen phenotype precipitated detachment,
signifying loss of cell viability. The effect was significantly more pronounced for cells transduced with the
G1 and G2 lentivirus.
We then stained podocytes transduced with APOL1G0 and APOL1Vs with PI and Hoechst 33342 and
examined these cells under an inverted fluorescence microscope. Interestingly, the swollen cells also
contained swollen nuclei (Fig. 3C) and were either necrotic or experiencing necrosis.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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Since APOL1WT expression inflicted podocyte injury, we asked whether injury was podocyte APOL1
expression dependent. To determine the effects of lowering expression of APOL1, podocytes were infected
with half the dose of lentivirus (titrated as 0.4 pg p24 protein/cell) for 3 h and then incubated in fresh
media for 48 h. Live and swollen cells were counted. As shown in Fig. 3, D and E, podocytes expressing
the APOL1WT did not display obvious podocyte injury; on the other hand, podocytes expressing G1 or G2
displayed a decreased percentage of viable cells and an increased percentage of swollen cells.
Since higher concentrations of APOL1G0 induced podocyte injury, we asked whether an inflammatory
milieu has the potential to enhance podocyte G0 expression. Podocytes were incubated in media
containing different concentrations of interferon-γ (0, 1, 2.5, 10, and 20 ng/ml) for 48 h. Subsequently,
RNA was extracted and cDNA was probed for APOL1. As shown in Fig. 3F, interferon-γ enhanced
podocyte endogenous APOL1 expression in a dose-dependent manner. Thus elevated APOL1 expression
in response to an inflammatory milieu could have the potential to contribute to ongoing injury.
To visualize the effect of APOL1Vs on podocyte injury, we performed PI/Hoechst staining after infecting
the cells with the lentivirus at 48 hpi. APOL1Vs promoted both primary (PI stained single swollen nuclei)
and secondary (PI stained fragmented nuclei) necrosis compared with APOL1G0 (Fig. 4). Taken together,
these findings indicate that high levels of APOL1Vs are cytotoxic to human podocytes.
Knockdown of APOL1 doesn't increase podocyte injury. Gene mutation often leads to the loss of

functionality of the encoded protein, in turn causing a loss-of-function disease phenotype with recessive
inheritance (e.g., sickle cell anemia). To examine whether podocyte loss of function was involved in
APOL1-associated nephropathy, APOL1 expression was silenced in human podocytes [small interfering
(si) RNA-APOL1/podocytes], and then podocyte phenotype was examined. The siRNA-APOL1/podocytes
displayed a ∼60% decrease in protein expression (Fig. 5, A and B), confirming silencing of this gene.
However, this was not associated with induction of either LDH activity or cell loss (Fig. 5, C and D).
Moreover, siRNA-APOL1/podocytes did not display morphological alterations. These results suggest that
APOL1 is not essential for the short-term structural or functional integrity of podocytes. This supports the
notion that APOL1Vs-associated nephropathy is not due to the loss of baseline APOL1 functionality in
podocytes. It is also important to note that the APOL1 gene exists only in humans and several nonhuman
primates and appears to be dispensable in rodents and other mammals (3).
Overexpression of APOL1Vs increases podocyte lysosomal membrane permeability. Pérez-Morga et

al. (36, 45) reported that APOL1 promotes trypanosomal lysis by forming pores in lysosomal membranes.
We considered whether APOL1 could compromise podocyte integrity through a similar mechanism. To
test this, we compared the effects of APOL1G0 and Vs on podocyte lysosomal membrane permeability
(LMP), with LysoTracker to label lysosomes. Both G1 and G2 variants drastically decreased the number of
punctated structures (normal lysosomes) in podocytes compared with vector control (Fig. 6, A and B).
Such a decrease may represent a consequence of the dramatic necrotic response evident in Figs. 2–4. To
confirm the specificity of APOL1-induced effects on LMP, corresponding podocytes were stained with
Lucifer yellow. Vector-treated podocytes displayed containment of dye within lysosomes; on the other
hand, G1 or G2 podocytes displayed diffuse lysosomal leak of dye into the cytosolic and nuclear
compartments (Fig. 6, A–C).
Since leakage of lysosomal enzymes such as cathepsin L has been reported to cause podocyte injury (39,
41), we examined the leakage of podocyte lysosomal cathepsin L in response to transduction with the
APOL1G0 and APOL1Vs encoding lentivirus constructs. In these studies, cathepsin L labeling was carried
out using the Magic Red kit as described in MATERIALS AND METHODS. APOL1Vs podocytes displayed
diffuse distribution of cathepsin L in the cytosolic compartment; on the contrary, vector-treated podocytes
showed containment of cathepsin L within lysosomes (punctate morphology) (Fig. 6, D and E). In turn, a
consequence of enhanced LMP and lysosomal cathepsin L leakage is the degradation of the cytoskeletal
protein F-actin (41). To compare the effect of APOL1G0 with APOL1Vs on podocyte F-actin, control and
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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experimental podocytes were labeled for F-actin by using Alexa-labeled phalloidin. APOL1Vs podocytes
displayed scant actin filaments compared with both vector alone and APOL1G0 (Fig. 6, F and G). These
findings suggest that APOL1 variants could be compromising the actin cytoskeleton by enhancing
podocyte LMP.
A chloride channel blocker inhibits APOL1Vs-induced podocyte swelling. Since APOL1 has been

demonstrated to induce lysosomal membrane depolarization and continuous influx of chloride, and
subsequent osmotic swelling of the lysosomes in trypanosomes (36), we evaluated the effects of chloride
channel blockers on APOLVs-induced podocyte swelling. G1 and G2 podocytes were incubated in media
containing either buffer or the chloride channel inhibitor DIDS for 48 h. Subsequently, swollen and viable
nonswollen podocytes were counted. As shown in Fig. 6, H and I, the chloride channel inhibitor provided
protection against G1- and G2-induced podocyte injury.
Blocking membrane traffic attenuates APOL1Vs-induced podocyte injury. Since APOL1 is also a

secreted protein and normally present in the circulation, it could reach the lysosomal compartments via an
endosomal trafficking pathway (37). Therefore, we studied the effect of chloroquine (CQ), which blocks
this pathway. Chloroquine attenuated the number of swollen and dead cells in APOL1Vs podocytes (Fig. 7
, A and B). Similarly, changing the media every 12 h resulted in increased cell viability (Fig. 7C); these
findings indicated that uptake of secreted APOL1Vs partially contributed to podocyte injury.
To confirm the role of secreted APOL1, podocytes were incubated in media containing conditioned media
(CM; collected from vector-, G0-, G1-, and G2-expressing podocytes) for 36 h. Swollen cells and viable
cells were quantified. Podocytes treated with CM-G1 and CM-G2 displayed higher numbers of swollen
cells and lower numbers of viable cells compared with respective CM-vector and CM-G0 (Fig. 7, D and
E). These findings indicate that factor elaborated into the media in the CM-G1 and CM-G2 contributed to
podocyte injury.
APOL1Vs make podocytes vulnerable to adverse host factors. Only a percentage fraction of the

population with the APOL1 risk genotype actually develop chronic kidney disease, suggesting the need for
a secondary hit factor (42). Accordingly, we examined the effect of several anticipated adverse host factors
(AHFs) on the state of podocyte injury in the setting of the WT and APOL1Vs. To determine the effects of
such previously well-characterized AHFs, podocytes expressing vector, G0, G1, and G2 were exposed to
H2O2, hypoxia, TNF-α, puromycin aminonucleoside, and HIV for different time periods, as indicated in
Fig. 8. Subsequently, the percentage of viable cells was counted. AHFs decreased the number of living
cells both in human podocytes infected with vector and with APOL1G0. However, the effects of AHFs
were greatly augmented in podocytes expressing the APOL1 G1 and G2 risk variants. The most prominent
difference was observed in the case of the response to HIV. These findings indicate that podocytes
expressing APOL1 are more susceptible to injury in the presence of AHFs. Thus it seems likely that
depending on the severity of such secondary hit AHFs, and the degree of APOL1 expression, podocytes
may pass a threshold of injury sufficient to cause progressive nephropathy. In this regard, it is noteworthy
that some of the AHF's which cause greater injury in podocytes expressing risk versions of APOL1 might
themselves also induce the expression of APOL1. This would be the case especially for HIV and possibly
other viral pathogens, which elicit an interferon-γ response (17).

DISCUSSION

Go to:

There have been many clinical reports suggesting the role of APOL1Vs in the development of APOL1associated nephropathy. However, to date there is a paucity of information in in vitro studies exploring the
mechanism. Accordingly, this study was conducted to test the biological effects of APOL1 and its variants
to determine whether there is a pathological counterpart to the differential effect of G0 and its kidney
disease risk association variants, in a potentially relevant cell type. We examined several potential
mechanisms wherein APOL1Vs could be causative in the greater susceptibility of African Americans to
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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progressive major forms of chronic kidney disease in the category of podocytopathies. Since even
APOL1G0 is toxic to cells when markedly overexpressed (47, 49), we titrated lentivirus-expressing
APOL1 non-risk and risk variants to achieve levels of expression wherein G0 would have minimal
toxicity. At the same doses, G1 and G2 display cell toxicity. These findings provide the first clear-cut
biological, functional counterpart to the observed association studies and validate the variants as being
causative and not only associated with cellular injury. Podocyte injury was evident as the increased
percentages of swollen and necrosed cells. However, higher levels of G0 expression also increased LDH
activity, decreased cell viability, and enhanced LMP and necrotic cell death; moreover, comparably high
levels of G1 or G2 still further enhanced the manifestation of these phenotypes. These findings suggest
that at comparable lower levels of expression, the G1 and G2 variants of APOL1 are more conducive to
podocyte cell injury compared with G0 or APOL1WT. This is potentially relevant to the formulation of a
threshold effect as an explanation for the recessive or two-risk allele inheritance mode, as has been
consistently reported (18).
The absence of a cellular phenotype after knockdown of endogenous APOL1 in human podocytes is also
consistent with the observation that APOL1 is dispensable for kidney integrity (22). Interestingly, frequent
changes of incubation media decreased APOLVs-induced podocyte injury, while direct exposure of
conditioned media of G1 or G2 promoted podocyte injury; these findings indicate that a secretory
component of APOL1Vs contributes to podocyte injury. Thus it is premature to dismiss the potential
contributory roles of both intracellular and secretory APOL1 gene products in the pathophysiology of
kidney injury in different clinical states and perhaps reflecting isoforms of APOL1 with differences in the
signal peptide domain (8). Since chloroquine partially attenuated APOL1-induced podocyte injury, a role
of endosomal traffic in transport of APOL1 may be inferred. Interestingly, the chloride channel inhibitor
DIDS attenuated APOL1-induced podocyte swelling; these findings indicate that secretory effector
molecule(s) transported via membrane trafficking may be targeted to lysosomes, in turn contributing to
abnormal chloride influx and lysosomal swelling. As a cellular organelle, the lysosome is a membranebound vesicle loaded with low pH-dependent hydrolytic enzymes. The integral double-layer membrane
around lysosome limits these enzymes within the lumen and protects the cytosolic proteins from
degradation. Increasing LMP will lead to the leakage of lysosomal enzymes into the cytosol, resulting in a
series of severe cell injuries, including cytoskeleton degradation, apoptosis, and necrosis (1, 4, 5, 20). In
the present study, overexpression of APOL1G1 and G2 in podocytes dramatically increased both LMP and
the leakage of lysosomal components into the cytosol, which was also accompanied by APOL1-induced Factin degradation and necrotic cell death in podocytes.
In this study, chloroquine, a known membrane traffic blocker, partially attenuated APOL1Vs-induced
podocyte cell injury; moreover, the change of media every 12 h also provided partial protection against
APOL1Vs-induced podocyte injury. Direct exposure of the conditioned media of G1 and G2 to podocytes
inflicted podocyte injury. All of these findings indicate that uptake of secreted APOL1Vs through
endocytosis might have also contributed to podocyte injury and that abnormal chloride flux could be
contributing to osmotic lysosomal swelling, overwhelming the capacity to remove damaged lysosomes.
Lysosome-mediated cell injury is also consistent with the observations of Perez-Morga et al. (36)
displaying the effect of APOL1 on the depolarization of lysosomal membranes and continuous influx of
chloride. Since it appears from the current findings that endosomal pathways may be required for APOL1
to target lysosomes, as also suggested by other investigators studying APOL1-induced lysosomal injury
(36, 45), modulation of such membrane traffic, in addition to chloride channel blockade, could be used as a
potential therapeutic means to ameliorate APOLVs-induced podocyte injury. Nonetheless, it will be
important in future studies to delineate the details of the membrane traffic pathways and their role in the
induction of podocyte lysosomal injury associated with APOL1Vs.
Genetic epidemiological studies have demonstrated that, while the odds ratios for kidney disease risk are
high in association with APOL1Vs, only a small percentage of the population with harboring of APOL1Vs
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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actually develops kidney disease. This suggests that genetic susceptibility is combined with a nongenetic
second, which transforms risk to disease causation. This is especially prominent in the case of HIVAN,
wherein in the absence of APOL1 genetic susceptibility HIVAN is rare to absent, and in the presence of
APOL1 genetic susceptibility, poor control of HIV viral load leads to HIVAN with a very high likelihood
(3, 11). To examine the pathobiological underpinnings of this second-hit formulation, we evaluated the
effect of G0, G1, and G2 versions of APOL1 in the presence of AHFs such as H2O2, hypoxia, TNF-α,
puromycin aminonucleoside, and HIV. AHFs induced only mild podocyte injury in vector- and G0expressing cells; however, the injury's effect was more pronounced on top of a higher level of baseline
injury in G1 and G2 podocytes. Thus it appears that both the expression levels of APOL1 and severity of
one or more second hits may determine the sustenance of podocyte injury, past a threshold which may not
be altered by compensatory mechanisms utilized for the maintenance of integrity of the glomerular
filtration barrier (16).
Consistent with the clinical and epidemiological observations, the second-hit counterpart was the most
pronounced in the case of HIV. Among individuals with APOL1Vs genotypic susceptibility, >50% will
develop HIVAN, which is about 10 times higher than those without HIV infection. This type of injury can
be mitigated by successful viral control (2, 25, 30, 32). These studies indicate that APOL1Vs may cause
particularly severe renal injury in the setting of HIV infection. In a previous study, we noted that HIV
increased lysosomal enzyme cathepsin L activity, which further compromised the integrity of the podocyte
cytoskeleton (7). Taken together, we speculate that APOL1Vs and HIV may act synergistically on such
lysosomal damage, leading to enhanced leakage of lysosomal components, exceeding the capacity to deal
with damaged lysosomes by normally available pathways, and stronger cytosol cathepsin L activity than in
the case of either APOL1Vs or HIV alone. This could be a possible mechanism for the prominence of the
association of APOL1Vs with HIVAN. Thus it appears that both the expression levels of APOL1 and the
severity of a second hit act in concert to determine the extent of podocyte injury. In patients, there may
also be compensatory repair mechanisms utilized for the maintenance of integrity of the glomerular
filtration barrier.
Although we observed that APOL1 variants would lead to podocyte loss, the underlying molecular
mechanism is still unknown. The T. brucei subspecies rhodesiense and gambiense resist the lytic activity
of Apol1WT and can infect humans, causing sleeping sickness (29). In the case of Tbr, resistance, their
lysis involves interaction of the SRA protein with the C-terminal helix of APOL1 (14, 19, 25). This
observation led us to believe that there may be functional SRA analogs in human serum or on the cell
vesicle membranes. We propose that it would be important to examine whether the APOL1 protein may
have the capacity to cause lysosomal membrane damage, while this toxic function is blocked in the WT
through binding to such a functional SRA homolog at the C terminus. To examine this possibility, we
constructed an artificial G1/G2 APOL1 variant containing both mutations of G1 and G2 on the same
sequence. We observed that expression of G1/G2 showed far greater toxicity to podocytes compared with
G1 or G2 alone. For example, trypan blue staining showed a ratio of dead cells at 48 hpi was close to 50%
for either G1 or G2, but 70% for the combined G1/G2 construct (data not shown). These findings are
consistent with the gain-of-injury formulation noted and provide a potentially important tool to screen for
protective molecules. While the current study focused on the effects of APOL1 on podocytes in culture,
this does not exclude additional sites of expression, cellular targets, or mechanisms. We also recognize that
cells in culture can amplify and accelerate cellular injury processes, causing them to appear in relatively
shorter time periods, compared with the corresponding clinical situations. This may be attributed to lack of
compensatory defense and repair mechanisms, which apply in the whole organism. Cell culture systems
amplify effects, which take longer or are milder in vivo, and this can be attributed to a hostile cell growth
environment with an absence of biological matrices, reduced serum factors, and induction of increased
cellular expression of protein. Nevertheless, this platform has enabled the clear-cut discernment of
differential biological effects of APOL1 and its variants in a relevant experimental platform that has been
used extensively in the past to study mechanisms involved in podocytopathies. By titrating expression of
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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APOL1 G0 to levels which did not induce podocyte injury, but in which corresponding levels of G1 and
G2 expression did inflict such injury, together with the differences in degrees of injury at higher
concentrations using multiple assays, and the augmented adverse host factor effects, this study provides
compelling preliminary evidence that extends beyond genetic association and should enable causative
mechanisms to be examined.
In summary, overexpression of APOL1G0, G1, and G2 are toxic to podocytes. However, importantly, the
APOL1 G1 and G2 variants induce a greater degree of podocyte injury, which manifests in the form of
cellular swelling and necrosis. This effect is accompanied by evidence of enhanced LMP, F-actin
disruption, and can be blocked partially by chloroquine and a chloride channel inhibitor. It is very likely
that many other mechanisms may be involved, as those cells other than podocytes may be targeted as well.
Nevertheless, as far as current literature is concerned, this is the first report of a differential effect of
APOL1 risk variants on cellular function in kidney cells and therefore provides a platform for unraveling
the molecular interaction that is responsible. On that account, the present study provides insight into the
mechanisms involved in APOL1-associated nephropathy and would help to set up high-throughput
compound screening and potential prevention and therapy for APOL1-associated nephropathy.
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Fig. 1.

Overexpression of APOL1 in human podocytes. Differentiated human podocytes were transduced with a lentivirus
[titrated as 0.8 pg human immunodeficiency virus (HIV) p24 protein/cell] for 3 h and were cultured in fresh medium. Cell
lysates were collected at 24 (A) and 48 (C) h postinfection (hpi) and were subjected to Western blot assay. B and D:
quantification of the expression of APOL1 in A and C, respectively, and the results are means ± SD of 3 independent
samples. V, vector alone; W, APOL1, wild-type (WT); G1, APOL1 G1 variant; G2, APOL1 G2 variant. *P < 0.05
compared with control (vector).
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Fig. 2.

APOL1 risk variants increase podocyte injury. Human podocytes were transduced with the lentivirus (titrated as 0.8 pg
HIV p24 protein/cell) for 3 h and were cultured in medium containing 1% serum. A: medium was collected for lactate
dehydrogenase (LDH) activity determination at 24 h hpi. B: cells were detached with Accutase and subjected to trypan
blue staining at 48 hpi. *P < 0.05 compared with vector. #P < 0.05 compared with APOL1WT.
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Fig. 3.

Open in a separate window
APOL1 risk variants increase podocyte swelling. A–C: human podocytes were transduced with the lentivirus (titrated as
0.8 pg HIV p24 protein/cell) for 3 h and were cultured in the fresh medium for 48 h. Swollen cells (black arrows) were
visualized (A) and counted (B) under a contrast-phase microscope. C: swollen cells were stained with propidium iodide
(PI) and visualized under a contrast-phase microscope. D and E: human podocytes were infected with half the dose of
lentivirus (titrated as 0.4 pg HIV p24 protein/cell), and swollen cells (D) and living cells (E) were counted. Scale bars =
100 and 20 μm for A and C, respectively. *P < 0.05 compared with vector. #P < 0.05 compared with APOL1WT. F:
podocytes were incubated in media in the absence or presence of different concentrations of interferon-γ (0, 1, 2.5, 10, and
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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20 ng/ml) for 48 h. Subsequently, RNA was extracted and cDNA was probed for APOL1 with qPCR. *P < 0.05 compared
with 0 interferon-γ.
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Fig. 4.

APOL1 risk variants increase podocyte swelling. Human podocytes were transduced with the lentivirus (titrated as 0.8 pg
HIV p24 protein/cell) for 3 h and were cultured in fresh medium. Cells were subjected to PI/Hoechst staining at 48 hpi.
Representative microphotographs (A) were selected to show the apoptotic (green arrow), necrotic (white arrow), and
secondary necrotic (yellow arrow) cells, and the ratios of these cells were calculated (B). Scale bars = 50 μm. *P < 0.05
compared with vector, while # P < 0.05 compared with APOL1WT.
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Fig. 5.

Knockdown of APOL1 does not increase podocyte injury. Differentiated human podocytes were transfected with small
interfering (si) APOL1 or siCon for 12 h and then were cultured in fresh medium for 48 h. A: cell lysates were collected
for Western blotting. B: quantification of the expression of APOL1 in A. Values are means ± SD of 3 independent
samples. NS, not statistically different. *P < 0.05 compared with siCon.
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Fig. 6.

Open in a separate window
APOL1 risk variants increase podocyte lysosomal membrane permeability. A–G: human podocytes were transduced with
the lentivirus (titrated as 0.8 pg HIV p24 protein/cell) for 3 h and were cultured in fresh medium for 48 h. LysoTrack red
(A and B) and Lucifer yellow (A and C) staining was performed. Cathepsin L activity (D and E) was detected with a
Magic Red Cathepsin L kit. F-actin (F and G) was detected with Alexa Fluor 594-conjugated phalloidin. Images were
captured with a confocal fluorescence microscope, and representative microphotographs were selected (A, D, and F).
Scale bars = 10, 20, and 100 μm for A, D, and F, respectively. The average fluorescence intensity was measured per region
of interest (ROI) for each group (B, C, E, and G). H and I. human podocytes were transduced with the lentivirus (titrated
as 0.4 pg HIV p24 protein/cell) for 3 h and were cultured in 1% serum medium with or without 100 μM DIDS for 72 h.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4121568/?report=printable
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Then, swollen cells (H) and living cells (I) were counted. *P < 0.05 compared with vector. #P < 0.05 compared with
control.
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Fig. 7.

Role of secretory APOL1 in podocyte injury. A and B: human podocytes were transduced with the lentivirus for 3 h and
were cultured in 1% serum medium with or without 2.5 μM chloroquine (CQ). At 48 hpi, swollen cells (A) and living
cells (B) were counted. *P < 0.05 compared with control group without chloroquine. C: human podocytes were
transduced with the lentivirus (titrated as 0.8 pg HIV p24 protein/cell) for 3 h and were cultured in fresh medium. After
every 12 h, medium was removed and cells were refreshed (washed) with new medium. At 48 hpi, cells were detached
with Accutase and were subjected to trypan blue staining *P < 0.05 compared with control (without wash). D and E:
human podocytes were transduced with the lentivirus (titrated as 0.8 pg HIV p24 protein per cell) for 3 h, then were
washed with PBS and cultured in fresh medium. At 72 hpi, the medium was harvested. After centrifugation, the
supernatant was collected as conditioned medium (CM) and was added to new human podocytes. After another 36 h,
swollen cells (D) and living cells (E) were counted. *P < 0.05 compared with vector. #P < 0.05 compared with
APOL1WT.
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Fig. 8.

Adverse host factors accentuate APOL1-induced podocyte injury. Human podocytes were transduced with the lentivirus
(titrated as 0.4 pg HIV p24 protein/cell) for 3 h and were cultured in fresh medium. After 24 h, H2O2 (600 μM), TNF-α
(100 ng/ml), or puromycin aminonucleoside (30 μM) was added. For hypoxia treatment, cells were moved into a 1%
oxygen incubator; for HIV treatment, cells were infected with pseudotype NL4–3 following the APOL1-expressing
lentivirus infection. After another 8 (H2O2), 24 (hypoxia, TNF-α, puromycin), or 48 h (HIV), cells were detached with
Accutase and were subjected to trypan blue staining. *P < 0.05 compared with control (without wash).
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